 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- | ebdarokimab (AK101) / Akesobio
Phase classification: Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 28, 2025
P2, N=330, Completed, Sponsor: Akeso
Phase classification: P2b --> P2
- | Journal: Prioritizing drug targets in systemic lupus erythematosus from a genetic perspective: a druggable genome-wide Mendelian randomization study. (Pubmed Central) - Aug 17, 2024
Repurposing and developing drugs targeting these genes is anticipated to improve the existing treatment state for SLE. Key Points
- ebdarokimab (AK101) / Akesobio
Long-term Safety and Efficacy of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Single Arm, Open Label, Multicenter Phase III Clinical Study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4793;
Key Points AK101 was generally safe and well tolerated, with good improvement in PASI 75 and sPGA0/1 response in Chinese subjects with moderate to severe plaque psoriasis.
- ||||||| ebdarokimab (AK101) / Akesobio
Trial completion, Trial completion date, Trial primary completion date: Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis (clinicaltrials.gov) - Jun 4, 2024
P3, N=950, Completed, Sponsor: Akeso
AK101 was generally safe and well tolerated, with good improvement in PASI 75 and sPGA0/1 response in Chinese subjects with moderate to severe plaque psoriasis. Recruiting --> Completed | Trial completion date: Jan 2023 --> Nov 2023 | Trial primary completion date: Jan 2023 --> Nov 2023
- ebdarokimab (AK101) / Akesobio
Efficacy and safety of AK101 in Patients with Moderate to Severe Plaque Psoriasis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1516;
AK101 was generally safe and able to improve PASI and sPGA0/1 response, as well as DLQI score in Chinese subjects with moderate to severe plaque psoriasis. There was no significant difference in the incidence of AEs between the AK101 group and the placebo group.
- ||||||| ebdarokimab (AK101) / Akesobio
Trial completion, Trial completion date, Trial primary completion date: A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis (clinicaltrials.gov) - Mar 2, 2023
P3, N=452, Completed, Sponsor: Akeso
There was no significant difference in the incidence of AEs between the AK101 group and the placebo group. Active, not recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Feb 2022 --> Sep 2022
- |||| ebdarokimab (AK101) / Akesobio
Trial completion, Trial completion date: Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 2, 2023
P2b, N=330, Completed, Sponsor: Akeso
Active, not recruiting --> Completed | Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Feb 2022 --> Sep 2022 Unknown status --> Completed | Trial completion date: Jul 2022 --> Mar 2022
- ebdarokimab (AK101) / Akesobio
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis: Withdrawn (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2128;
- |||||||||| ebdarokimab (AK101) / Akesobio
New P3 trial: Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis (clinicaltrials.gov) - Aug 22, 2022
P3, N=950, Recruiting, Sponsor: Akeso
- |||||||||| ebdarokimab (AK101) / Akesobio
New P3 trial: A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis (clinicaltrials.gov) - Nov 14, 2021
P3, N=450, Active, not recruiting, Sponsor: Akeso
- |||||| ebdarokimab (AK101) / Akesobio
New P2b trial: Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 21, 2019
P2b, N=280, Not yet recruiting, Sponsor: Akeso
- |||| ebdarokimab (AK101) / Akesobio
New P1/2 trial: A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 20, 2019
P1/2, N=96, Completed, Sponsor: Akeso